Resistant to extreme temperatures (-196ºC to 388ºC), chemicals & solvents, alcohol, humidity & moisture, CILS 8/9100 sample I.D labels are fully printable straight from a standard laser, inkjet or thermal transfer printer allowing variable data (batch no’s, barcodes, etc) to be added ‘in minutes’, saving time and eliminating the risk of smudged/illegible handwritten data. The specially formulated, high-tack adhesive also provides permanent long-term adhesion to all labware.
The new Sens Point handheld lactate analyser is designed for professional use with built-in connectivity functions to hospital or lab information systems. The measuring time is only 10 seconds using 0.2μl sample volume. The handheld analyser has a lightweight, ergonomic design and is highly accurate, offering excellent correlation to lab analysers. Its intuitive user interface utilizes a large high resolution colour display. The device also features an integrated barcode scanner. Results can be linked to operator ID, patient ID, time, date and LOT number of sensors, allowing traceability of users and eliminating use by untrained staff. Results are printable using a small external Bluetooth-enabled printer.
Read more
For the automated isolation of cells directly from whole blood or buffy coat, LIAISON Ixt/ Arrow CellSep Advanced can isolate up to 3 cell types per sample in just 32 minutes per cell type, offering significant time savings compared to manual cell separation methods. Based on proven magnetic bead technology, CellSep Advanced is designed for use on the LIAISON Ixt/ Arrow instrument for the separation of 1, 2 or 3 cell types in up to 12 samples at a time. Requiring minimal hands-on intervention, the system produces good yields of purified cell preparations ready for use in a wide range of downstream applications, including lineage-specific chimerism analysis. The Ixt/Arrow automated platform also minimizes human error and ensures reproducibility between runs for consistent and reliable downstream analysis. Trials have shown that the performance of CellSep Advanced is equivalent to manual cell separation methods, in terms of cell quality and quantity. The product is part of a growing range of cell separation and nucleic acid extraction kits available for use on the LIAISON Ixt/ Arrow instrument, meeting the demands of modern cell analysis applications and ensuring that reliable results are reaching clinicians at the earliest opportunity.
Read more
Oxcarbazepine is a pro-drug indicated for treatment of partial seizures, a form of epilepsy. Serum concentrations (3-35 mg/L) of the active monohydroxy derivative (MHD) metabolite are associated with clinically effective control of partial seizures. Toxic side effects may occur more commonly at concentrations greater than 35 mg/L. Therapeutic drug monitoring (TDM) is justified when changes are expected that might alter MHD clearance including pregnancy, concomitant use of liver enzyme inducing drugs, or renal insufficiency. The ARK Oxcarbazepine Metabolite Assay is a homogeneous enzyme immunoassay intended for the quantitative determination of MHD in human serum on automated clinical chemistry analysers. The ARK Oxcarbazepine Metabolite Assay is available for export outside the US. It has not received clearance/approval by the U.S. FDA.
Read more
The traditional method of diagnosing vitamin B12 deficiency has been to measure the concentration of total vitamin B12 in serum. The total vitamin B12 concentration essentially reflects vitamin B12 which is bound to its two carrier proteins, forming holohaptocorrin (holoHC) and holotranscobalamin (holoTC). Whilst holoHC accounts for 70 % – 80 % of the vitamin B12 in serum, only holoTC (active vitamin B12) can be used by human cells. Measurement of total vitamin B12 can therefore give erroneous results because it measures the circulating vitamin B12 but does not reflect the level of active vitamin B12. The Biohit Active B12 (Holotranscobalamin) ELISA test directly measures holoTC – the biochemically active form of vitamin B12 – in human serum. This test is well suited for the screening of patients with suspected vitamin B12 deficiency. It can also be used for confirming vitamin B12 status in the large number of patients receiving an inconclusive total vitamin B12 test result.
The Endura MD mass spectrometer LC-MS for in vitro diagnostic use delivers excellent sensitivity for a wide range of compounds and matrices and minimizes signal noise by removing more solvent vapour and blocking neutrals. The instrument provides five orders of dynamic range for accurate quantitation of even low-concentration or limited samples and features ultrafast selected-reaction monitoring (SRM) so more transitions can be monitored for greater confidence. It accommodates both HESI and APCI probes, which can be operated in either positive or negative ion modes to meet varied analytical demands.
A comprehensive range of anti-Chlamydia test systems provides reliable serological diagnosis of infections with C. trachomatis, C. pneumoniae and C. psittaci. Serological methods are an important supplement to direct pathogen detection in the diagnosis of primary Chlamydia infections. They are, moreover, particularly useful for diagnosing persistent infections and for identifying long-term consequences of infection, such as sterility or reactive arthritis following C. trachomatis infection. The gold standard for detecting Chlamydia antibodies is microimmunofluorescence (MIF). The Anti-Chlamydia MIF provides BIOCHIP substrates of elementary bodies of C. trachomatis, C. pneumoniae and C. psittaci for parallel detection of the corresponding antibodies. The mutual lipopolysaccharide (LPS) antigen is inactivated to minimize cross reactivity. A control BIOCHIP of non-infected cells allows secure differentiation of unspecific and specific reactions. Anti-Chlamydia antibodies can also be detected using ELISA or immunoblot. The Anti-Chlamydia trachomatis ELISA utilizes native major outer membrane protein (MOMP) as the antigen for species-specific antibody detection. The Anti-Chlamydia pneumoniae ELISA is based on a cell lysate and allows genus-specific antibody detection. The immunoblot Anti-Chlamydia trachomatis EUROLINE-WB contains a unique combination of three categories of antigen: Chlamydia cross-reactive LPS, highly specific antigens from elementary bodies of C. trachomatis and highly specific recombinant MOMP antigen. This broad antigen spectrum ensures high sensitivity and specificity in the detection of antibodies against C. trachomatis. All anti-Chlamydia test procedures can be automated using specialized automation systems.
Infections by carbapenemase-producing Enterobacteriaceae (CPE) are the cause of major public health concern worldwide and their detection is very challenging for diagnostic laboratories. Classical identifications need 48 to 72 hours with cultures and susceptibility testing followed by phenotypic and molecular methods. Development of new rapid diagnostic tests to track antimicrobial resistance patterns is considered as a priority core action. Non-molecular confirmatory testing of Class A (KPC) and B (VIM, IMP, NDM) carbapenemases already exists but not for detection of Class D carbapenemase (OXA-48-like). Phenotypic colorimetric assays are not able to confirm OXA-48 presence, while molecular tests need a dedicated environment, skilled staff and are expensive. Coris BioConcept has developed a new assay for identifying OXA-48 carbapenemase in collaboration with the CPE Belgian National Reference Centre of CHU Dinant-Godinne UCL. This test is performed directly from a single colony and represents the first non-molecular confirmatory assay for OXA-48 detection with results available in minutes.
Although many POCT devices offer ‘built in’ QC, a truly independent, unbiased assessment of system performance is only possible through the use of third party controls, something that is reflected by ISO 15189 guidelines.
As a leading provider of complete quality control solutions, Randox manufacture a range of highly convenient quality controls ideally suited to POCT due to their liquid stable, ready-to-use format and easy storage. Combining multiple parameters at clinically significant levels in a single control material not only enables test menu consolidation but can help to reduce time and costs. Principle control products include the Acusera Liquid Cardiac Control covering 8 commonly tested cardiac markers, the Acusera Blood Gas Control containing 10 parameters in total and the Acusera Urinalysis Control comprising a total of 13 parameters.
Read more
DiaSorin has further expanded its range of infectious disease assays for use on the DiaSorin Liaison Iam analyser with the launch of a new molecular assay for the rapid and reliable detection and quantification of cytomegalovirus (CMV). CMV is the most prevalent infectious pathogen in solid organ and bone marrow transplant recipients, and can lead to allograft rejection and other serious complications. The DiaSorin Iam CMV assay is used to detect and quantify clinically relevant subtypes of CMV in human plasma, urine and cerebrospinal fluid (CSF), making it a valuable tool for the diagnosis and monitoring of CMV infection in transplant recipients and other immunocompromised individuals. Reactivation of latent CMV infection can occur in immunocompromised individuals. With increasing numbers of transplant recipients, as well as expanding indications for immune-modulating agents, the number of people at risk of CMV disease and related complications is increasing. The direct and indirect effects of CMV infection can have a significant impact on outcomes for transplant recipients. Furthermore, CMV is a major cause of morbidity in AIDS patients and in others with impaired immunity, for example due to sarcoidosis, lymphoma and corticosteroid therapy. Clinical manifestations amongst these patient groups include retinitis, pneumonitis, gastrointestinal disease and neurological disorders. Based on the innovative DiaSorin Q-LAMP technology, Iam CMV is the latest addition to an expanding portfolio of infectious disease assays for use on the DiaSorin Liaison Iam analyser. It is a molecular assay for the detection of CMV in human amniotic fluid and for the detection and quantification of the virus in human plasma, urine and cerebrospinal fluid (CSF). Iam CMV has been standardized against the WHO CMV International Standard (NIBSC, UK), as recommended in the updated International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation. With excellent intra-run precision (≤ 0.3 log cps/mL) and with diagnostic sensitivity (≥97%) and specificity (100%) comparable to conventional PCR, but with results in a fraction of the time required by PCR, Iam CMV provides a rapid and accurate method for the timely diagnosis and monitoring of CMV infection. The small footprint, ease of use and scalable design of the benchtop Liaison Iam Molecular Instrument makes it ideal for use in laboratory facilities of all sizes, including those that are located close to the patient. In addition to being used for the detection and monitoring of CMV infection in immunocompromised individuals, Iam CMV is also used in the diagnosis of maternal and fetal CMV infection in early pregnancy and for monitoring CMV infection in affected babies. The Iam CMV assay is CE marked and available for use outside of the USA and Canada.
March 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.